Psychedelic Sector Overview
Psychedelic Sector Overview
Opening Remarks
This overview seeks to map out the rapidly expanding psychedelic sector landscape via a focus on different stages of the supply chain, and a variety of specialisms. Naturally, some companies appear in multiple segments.
Clicking on a company logo will present a brief summary of the company’s activity within that segment, plus a link for further information.
This page is updated frequently, with companies being added as-and-when they exhibit substantial activity in a given segment. Your comments and suggestions are welcome and can be directed to industry@psilocybinalpha.com.
Industry Segments
Supply, Manufacture
Cultivation, synthesis, and other production of psychedelics
Psygen
- Private Company -
Psygen manufactures synthetic psychedelic drugs, which they provide to organisations conducting clinical research. The Company claims to be the first manufacturer of restricted psychedelic drug products licensed by Health Canada.
Psygen's pilot project is licenced to manufacture psilocybin, MDMA, LSD, DMT, mescaline and 2C-B. The pilot operates at the University of Alberta under the licence of Dr. Raimar Löbenberg.
The Calgary-based company has applied to Health Canada for a corporate Dealer’s License which will allow them to manufacture, possess, sell, import, export and analyze psychedelic substances. The company is actively developing and constructing their 6000 sqft lab capable for synthesis, formulation and distribution.

Synthetic manufacture
Numinus
In October 2020 Numinus became the first public company to harvest a legal flush of Psilocybe mushrooms in Canada. The Company completed the harvest under its Controlled Drugs and Substances Dealer’s Licence.

Cultivation
CB Therapeutics
- Private Company -
CB Therapeutics is engaged in the biosynthesis of tryptamines such as psilocybin, psilocin, and their analogs. The company claims to be the first to file intellectual property for the production of these compounds in yeast.

Synthetic manufacture
Octarine Bio
- Private Company -
Octarine Bio believes that its synthetic biology approach to producing psychedelic molecules will generate more consistent, pharmaceutical-grade yields at comparatively low costs.
The Company claims that the costs associated with their yeast fermentation method are at least 1,000 times lower than existing methods of psilocybin extraction.

Synthetic manufacture
PsyBio Therapeutics
TSXV: PSYB
PsyBio Therapeutics is exploring the production of biosynthesised psilocybin and other psychoactive molecules. The process involves the use of genetically modified bacteria (such as E. coli) as part of a patent-pending process.

Synthetic manufacture
Field Trip
CSE: FTRP | OTC: FTRPF
Field Trip's Jamaican subsidiary is in the process of constructing a research and cultivation facility on the University of the West Indies' Mona campus. Note that Psilocybin is legal in Jamaica.

Cultivation
Havn Life
CSE: HAVN | OTC: HAVLF
Havn Life has applied for Licensed Dealer status from Health Canada, which it hopes to secure by 2021.
In anticipation of securing this licence, Havn has entered into a supply agreement with Revive Therapeutics to source naturally-derived psilocybin (and possibly other psychedelic compounds).

Licence pending
New Wave Holdings
CSE: SPOR | OTC: TRMNF | FWB: 0XM2
New Wave owns two farms in Jamaica, where psilocybin is legal. The company explains that it will operate two facilities on these farms for cultivating and processing psychedelics and mushrooms.

Cultivation
Mydecine
CSE: MYCO | OTC: MYCOF | FWB: 0NF
In December 2020, Mydecine announced that it had completed a harvest of psilocybin mushrooms in Jamaica, and was preparing to export 20 kilograms to Canada under the Health Canada schedule 1 Dealer's Licence attached to its Canadian R&D facility.

Cultivation
R&D, Clinical Trials
Research and development and/or clinical trials involving psychedelics.
IP & Patents
Companies building psychedelics patent portfolios.
Compass Pathways
Nasdaq: CMPS
In 2019, Compass Pathways was granted a patent pertaining to treating drug-resistant depression with their synthetic psilocybin formulation 'COMP360'.
Compass has two further patents pending in the US, and has publicly admitted that intellectual property is central to their commercial success.
View our Psilocybin Patent Tracker for further information.

Patents granted, pending
CaaMtech
- Private Company -
An early mover in the psychedelics space, CaaMTech has two psilocybin-related patents pending in the US. Both were filed in 2017.
Both concern psilocybin derivatives, some combined with cannabinoids, for the treatment of psychological disorders.
November 2020 update: one patent application has been allowed. More information to follow.
View our Psilocybin Patent Tracker for further information.

Patent application allowed
Field Trip
CSE: FTRP | OTC: FTRPF
In September 2020 Field Trip filed a US Provisional Application covering its FT-104 molecule, which it claims to be a unique and commercially viable alternative to substances such as psilocybin, DMT and LSD.
View our Psilocybin Patent Filings Tracker for further information.

Provisional patent application
CB Therapeutics
- Private Company -
In December 2019, CB Therapeutics filed a US Provisional Application for a patent covering the biosynthesis of psilocybin, psilocin and related tryptamine-based compounds typically found in plants and fungi.
While this is only an application, it should be noted that CB Therapeutics has been granted patents unrelated to psychedelics in the past.
View our Psilocybin Patent Filings Tracker for further information.

Provisional patent application
Revive Therapeutics
CSE: RVV | OTC: RVVTF
Revive Therapeutics has filed a number of Provisional Applications in the US pertaining to methods of production of psilocybin-based formulations, including sublingual sprays, effervescent tablets, hard-shell capsules, etc.; plus methods of psilocybin extraction and crystallisation.
View our Psilocybin Patent Filings Tracker for further information.

Provisional patent applications
Eleusis
- Private Company -
Eleusis has one published, and one pending, patent pertaining to psilocybin. The published patent relates to the screening of candidates for treatment with a psychedelic agent, including psilocybin.
The pending patent relates to improving mental or physical wellbeing via the administration of a psychedelic, including psilocybin.
View our Psilocybin Patent Tracker for further information.

Patents published, pending
Tryp Therapeutics
CSE: TRYP
In 2019 and 2020, Tryp Therapeutics has filed two provisional patent applications:
- PCT/IB2020/058597: Compositions and Methods to Improve the Therapeutic Benefit of Bis-Dioxopiperazines
- PPA 63/017,404: Therapeutic Methods Using Psilocybin
The company intends to further utilise patents, trade secrets, and other methods of protecting their IP as they proceed with R&D and clinical trials.

Provisional patent applications
Cybin
NEO: CYBN | OTC: CLXPF
Cybin has filed at least 8 provisional patent applications covering a range of technologies and psychedelic molecules: from an oral film delivery mechanism to deuterated psychedelic molecules and analogues.
You can learn more in their press release here.

Provisional patent applications
MagicMed
- Private Company -
MagicMed is developing a library of molecular derivatives that it calls the Psybrary™. Natural psychedelic molecules such as psilocybin are modified to create novel derivatives, which (unlike the natural molecules themselves) can be eligible for patents. Proprietary methods of manufacturing these molecules may also be patented.
Initially, the Psybrary™ will focus on psilocybin.
View our Psilocybin Patent Filings Tracker for further information.

Provisional patent applications
Silo Pharma
OTCQB: SILO
In January 2021, Silo Pharma announced a $1m patent licence agreement for psilocybin and cancer-related applications. Note that, at this time, Silo has not been granted any patents; rather, it has submitted provisional patent applications to the USPTO.

Provisional patent applications
As with other categories, this is not exhaustive. You can view further companies that have filed psilocybin-related patent applications via our Tracker – more compounds to follow.
Delivery: Clinics, Retreats
Companies delivering psychedelic therapies via clinics, retreats, etc.
Field Trip
CSE: FTRP | OTC: FTRPF
Field Trip operates a number of ketamine-assisted therapy clinics in Canada and the United States.
The company intends to provide psilocybin truffle-assisted therapy in Amsterdam, beginning March 2021.

Ketamine clinics
Champignon Brands
CSE: SHRM | OTC: SHRMF | FWB: 496
Champignon Brands offers ketamine therapy via the Canadian Rapid Treatment Centre of Excellence.
The company also owns and/or operates other ketamine clinics, such as the Wellness Clinic of Orange County in US.

Ketamine clinics
Novamind
Soon to Go Public
Novamind has a network of ketamine clinics and psilocybin retreat providers.
This includes the Synthesis Institute, providing psilocybin retreats in the Netheralnds.

Ketamine clinics, psilocybin retreats
Wake
- Private Company -
Wake offers 4-6 day 'clinical immersions' in a diverse range of locations including Jamaica, Santa Cruz, and Brazil (coming soon).

Psilocybin retreats
MycoMeditations
- Private Company -
MycoMeditations offers week-long psilocybin mushroom retreats in Jamaica.
The Company has been operating since 2014, making it one of the earlier providers in the space.

Psilocybin retreats
Eleusis
- Private Company -
In December 2020, Eleusis announced their acquisition of Kalypso Wellness Centers, a provider of ketamine infusion therapies in the US. Kalypso had 7 centres at the time of acquisition, 6 in Texas, one in New York.

Ketamine clinics
Numinus
TSXV: NUMI | OTC: LKYSF
In December 2020, Numinus announced its acquisition of Mindspace Wellbeing, a Montral-based ketamine clinic.

Ketamine clinics
Synthesis
- Private Company -
Synthesis offers psychedelic retreats in Amsterdam, where psilocybin truffles are legal.
The company collaborates with the Centre for Psychedelic Research at Imperial College London, sharing guest data to understand whether, and/or how, psilocybin truffles may improve the wellbeing of participants.

Psilocybin retreats
Psychedelic Insights
- Private Company -
Based out of Amsterdam, the Netherlands, Psychedelic Insights provides legal, safe, psychologically guided psychedelic experiences, to individuals, groups, and professionals, with magic psilocybin truffles for personal development.

Psilocybin experiences
ATMA Journey Centers
- Private Company -
Psilocybin-assisted therapy 'journey center' opening in Alberta.

Psilocybin experiences
As with other categories, this is not definitive. Comments are welcome at industry@psilocybinalpha.com
Drug Delivery Methods
Companies exploring drug delivery methods for psychedelic therapies.
Revive Therapeutics
CSE: RVV | OTC: RVVTF
Revive Therapeutics has filed several provisional patent applications covering psilocybin delivery methods including hard-shell capsules; effervescent and tablets; gum drops; oral strips and transmucosal thin-film; sublingual and buccal.
In November 2020, the company announced it had finalised prototype of the oral thin-film delivery system.
You can learn more about these provisional patent applications on our Psilocybin Patent Filings Tracker.

Provisional patent applications
MindMed
NEO: MMED | OTC: MMEDF | FWB: BGHM
MindMed filed a patent application for an LSD neutralizer technology intended to shorten and stop the effects of an LSD trip.
You can learn more about this provisional patent applications on our Psilocybin Patent Filings Tracker.

Provisional patent application
Cybin
NEO: CYBN | OTC: CLXPF
Cybin is developing orally-dissolving psilocybin film for the delivery of psilocybin. The company has a feasibility agreement with IntelGenx for the development of this product.

Feasibility agreement
NeuroPharm
Subsidiary of Mydecine:
CSE: MYCO | OTC: MYCOF | FWB: 0NF
NeuroPharm, a subsidiary of Mydecine, has filed a provisional patent application for a delivery method for treatment of PTSD with psilocybin.
You can learn more about these provisional patent applications on our Psilocybin Patent Filings Tracker.

Provisional patent application
Silo Wellness
Soon to Go Public
Silo Wellness has a published patent application for a delivery method for psilocybin with a nasal spray
You can learn more about these provisional patent applications on our Psilocybin Patent Tracker.

Published patent application
Lobe Sciences
CSE: LOBE | OTC: GTSIF
In December 2020, Lobe Sciences announced that it engaged VisionWorks Engineering of San Diego, CA to complete and test a proof of concept prototype of its nasal mist device.
"The Company holds several provisional patent applications including for a nasal mist device entitled “Device and Method for the Treatment of Traumatic Brain Injuries and Post-Traumatic Stress Disorder”. This device includes a nasal delivery system for administration of pharmaceutical agents such as a psilocybin-derived agent and/or NAC at preselected dosages and times. The device design allows for the precise control and delivery of medicines through the nasal cavity for faster and more efficient uptake of psychedelics and other medicines that target the brain."

Provisional patent application
As with other categories, this is not definitive. Comments are welcome at industry@psilocybinalpha.com
Industry Tech, Telemedicine
Companies developing industry software and applications, and psychedelics telehealth companies.
MindMed
NEO: MMED | OTC: MMEDF | FWB: BGHM
In November 2020 MindMed announced the intention to launch 'Albert', a new division of the company dedicated to digital therapeutics.
MindMed previously announced that it is working on a piece of technology that aims to optimise dosing of MDMA, LSD and other psychedelics based on a patient's profile.

Digital therapeutics (plans)
Field Trip
CSE: FTRP | OTC: FTRPF
Field Trip has published an app, called Trip, on the App Store and Play Store. The app intends to act as a guide for psychedelic experiences.
The company has also developed the Field Trip Portal, which it makes available to its clients.

App, web portal
Mindleap Health
Subsidiary of Mydecine:
CSE: MYCO | OTC: MYCOF | FWB: 0NF
Mindleap is a platform that seeks to connect people with mental health specialists to provide support and integration for psychedelics users.

Telehealth
Nutraceuticals and other CPGs
Companies providing consumer packaged goods such as functional mushrooms, nutraceuticals, etc.
Havn Life
CSE: HAVN | OTC: HAVLF
Havn Life Sciences has received Health Canada approval for a range of natural health product formulations, including mushroom mixes.
The company intends to launch the 7 product in 2021, on the Canadian market.

‘Health products’
NeonMind
Subsidiary of Better Plant Sciences
CSE: PLNT | OTC: VEGGF | FWB: YG3
NeonMind, a subsidiary of Better Plant Sciences, offers mushroom coffees.

Mushroom coffees
Wake
- Private Company -
Wake offers functional mushroom products, including various mushrooms in capsule form.

Functional mushrooms
Adult Use & Microdosing
Companies legally providing psychedelics for recreational use.
Red Light Holland
CSE: TRIP | OTC: TRUFF
Red Light Holland operates in the Netherlands via the sale of psilocybin-containing magic truffles - legal in the country.
In December 2020, the Red Light announced their intention to enter the Brazillian market.

Magic truffles (Netherlands)
PharmaDrug
CSE: BUZZ | OTC: LMLLF
PharmaDrug owns Super Smart, "an early-stage retail company focused on consolidating the fragmented Dutch smartshop market. Smartshops are retail establishments in The Netherlands that specialize in the sale of psychoactive substances including psychedelic truffles."

Magic truffles (Netherlands)
Earth Resonance
- Private Company -
Earth Resonance provides microdosing supplements for therapeutical use. Their products are in the form of Sclerotia, which contains Psilocybin - otherwise known as magic truffles. Their products are exclusively sold in the Netherlands

Microdose packs (Netherlands, magic truffles)
Suggestions & Comments
Psilocybin Alpha reserves its right to exercise editorial judgement regarding the inclusion of companies on this page, and does not claim that this resource is definitive. As with all of our resources, this sector landscape should not inform investment decisions.
If you would like to suggest an addition or amendment to this Psychedelic Sector Overview, you are welcome to contact us at industry@psilocybinalpha.com